BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
32 hedge funds and large institutions have $6.72M invested in BRAINSTORM CELL THERAPUTC in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 7 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
82% more call options, than puts
Call options by funds: $289K | Put options by funds: $159K
23% more funds holding
Funds holding: 26 → 32 (+6)
0.27% less ownership
Funds ownership: 0.85% → 0.58% (-0.27%)
27% less capital invested
Capital invested by funds: $9.23M → $6.72M (-$2.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$216K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$155K |
| 3 |
Renaissance Technologies
New York
|
+$99.5K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$98.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$88.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.76M |
| 2 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$471K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$70K |
| 4 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$25K |
| 5 |
BlackRock
New York
|
-$7.05K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
First Manhattan
New York
| $14K | +$15.1K | +233 | New |
|
|
AG
27
Advisor Group
Phoenix,
Arizona
| $8K | +$2.14K | +33 | +33% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $7K | +$7.7K | +119 | New |
|
29
Citigroup
New York
| $2K | – | – | – |
|
|
ASN
30
Advisory Services Network
Atlanta,
Georgia
| $2K | +$2.14K | +33 | New |
|
|
RE
31
RBC Europe
London,
United Kingdom
| $1.93K | +$2.01K | +31 | New |
|
32
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
SFM
33
Sphera Funds Management
Tel Aviv,
Israel
| – | -$2.76M | -55,576 | Closed |
|
|
JMPWA
34
JP Morgan Private Wealth Advisors
San Francisco,
California
| – | -$471K | -7,565 | Closed |
|
|
TC
35
TFS Capital
West Chester,
Pennsylvania
| – | -$87K | -1,396 | Closed |
|
|
SM
36
Sabby Management
Miami Beach,
Florida
| – | -$70K | -1,115 | Closed |
|
|
AIM
37
Acrospire Investment Management
Chicago,
Illinois
| – | -$25K | -407 | Closed |
|
38
Group One Trading
Chicago,
Illinois
| – | -$2.59K | -40 | Closed |
|
39
Simplex Trading
Chicago,
Illinois
| – | -$777 | -12 | Closed |
|
BCLI Hedge Fund Activity: Q3 2017 in Review
32 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2017, worth a combined $6.72M — down 27% from $9.23M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BCLI positions and 7 closed out — a net gain of 6 holders — while 7 added to existing stakes and 1 trimmed.
The largest buyer was CIBC Private Wealth Group, opening a new position worth an estimated $216K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.76M sold.
- 32 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2017, up from 26 in Q2 2017.
- Funds reported $6.72M of BRAINSTORM CELL THERAPUTC stock for Q3 2017, down 27% quarter-over-quarter.
- 13 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2017 and 7 closed out, a net change of +6 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2017 was CIBC Private Wealth Group, an estimated $216K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2017 was Sphera Funds Management, an estimated $2.76M sold.
Based on aggregated 13F filings for Q3 2017.